Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone-lysine N-methyltransferase SETD7 (commonly known as SET7/9) is a member of the SET domain-containing family of methyltransferases that specifically catalyzes the monomethylation of lysine 4 on histone H3 (H3K4me1), a modification associated with active gene transcription. Beyond histones, SET7/9 is unique in its ability to methylate a wide array of non-histone proteins, including the tumor suppressor p53, estrogen receptor alpha (ER-alpha), TAF10, DNMT1, and YAP, thereby regulating diverse cellular processes such as cell cycle progression, apoptosis, and signal transduction. Due to its involvement in pathological states like cancer progression, chronic kidney disease, and diabetic complications, SET7/9 has emerged as an attractive therapeutic target. Pharmacological inhibitors, such as the highly selective chemical probe (R)-PFI-2 and the repurposed drug cyproheptadine, target the substrate-binding pocket of the enzyme to block its methyltransferase activity. However, because of its context-dependent roles as both an oncogene and a tumor suppressor, as well as its broad physiological functions, therapeutic targeting of SET7/9 presents significant challenges regarding selectivity and safety.
Inhibition of histone-lysine N-methyltransferase activity, typically through substrate-competitive or cofactor-dependent mechanisms, preventing the monomethylation of histone H3 lysine 4 (H3K4me1) and non-histone substrates.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone-lysine N-methyltransferase SETD7 (SETD7).